Click here to go to back to the top of the page.

Pipeline

Our pipeline from Phase 1 to registration includes 90 investigational therapies, which are focused in areas where we have the potential to bring differentiated, high value therapies and vaccines to patients faster.

Programs in Clinical Trials or Registration

Our clinical research activities are focused on translating novel science into therapies and vaccines. Today, our clinical pipeline includes targeted immunotherapies, which have the potential to be part of the next generation of cancer therapy; first-in-class vaccines with the potential to help prevent two deadly hospital-acquired infections; antibodies that may be potentially useful in treating lupus and inflammatory bowel disease; and, a potential new therapy for Parkinson's disease. We are also applying our expertise in developing safe and effective biologic medicines to develop high quality biosimilars that may provide patients with access to alternative biologic therapies.

Pfizer Pipeline as of February 2, 2016

I'm Working On...
Click to play the video.
James Rusnak
Development Lead, Cardiovascular Metabolic Disease
Watch Video
I'm Working On...
Click to play the video.
James Rusnak
Development Lead, Cardiovascular Metabolic Disease
Watch Video
I'm Working On...
Click to play the video.
Brenda Cooperstone
Vice President, Category Development Lead, Rare Disease
Watch Video
I'm Working On...
Click to play the video.
Brenda Cooperstone
Vice President, Category Development Lead, Rare Disease
Watch Video
I'm Working On...
Click to play the video.
Lovisa Afzelius
Head of Computational Precision Medicine, Inflammation and Immunology
Watch Video
I'm Working On...
Click to play the video.
Lovisa Afzelius
Head of Computational Precision Medicine, Inflammation and Immunology
Watch Video
Back to Top